Page 48

Proefschrift binnenwerk Manon Ernst_DEF.indd

C H A P T E R   3   study   was   to   investigate   if   these   metabolic   effects   could   also   be   seen   in   SGA   chil-­‐ dren  treated  with  rhGH  after  6  weeks  and  whether  these  effects  are  also  a  predic-­‐ tive  tool  for  growth  response  after  one  year.   Importance  of  the  study   Until  now,  height  measurement  during  a  period  of  one  year  of  treatment  with  rhGH   is  recommended  for  a  reliable  evaluation  of  the  growth  response.  Because  the  eval-­‐ uation  of  the  effect  lasts  such  a  long  time,  some  children  are  unnecessarily  treated   with   rhGH,   consisting   of   daily   injections.   Besides,   growth   hormone   therapy   is   an   expensive  treatment.  To  prevent  unnecessary  treatment,  the  prediction  of  the  effect   of   rhGH   therapy   on   a   short   term   basis   is   important.   The   aim   of   this   study   was   to   find  a  good  prognostic  tool  for  prediction  of  the  growth  response  to  rhGH  therapy.     Methods   Subjects   In  this  study  children  with  GHD  or  SGA  were  included  who  were  indicated  for  rhGH   treatment  according  to  the  Dutch  Growth  Research  Foundation.  GHD  children  have   to  meet  the  following  criteria:   • Negative  deviation  of  the  growth  curve     • Delayed  bone  maturation  measured  by  X-­‐ray  of  the  left  hand     • GH  concentration  <  20mU/l  in  2  stimulation  tests     • Insulin-­‐like  growth  factor  1  (IGF-­‐1)  <  -­‐2  SD     • Inclusion  criteria  for  SGA  children  to  receive  GH  therapy  were:     • Birth  length  or  weight  <  -­‐2  SD  for  gestational  age     • Actual  height  <  -­‐2.5  SD  according  to  the  standard  reference  values14,15   • Age  ≥  4  years     • Bone  maturation  ≤  13  years  for  girls  or  ≤  15  years  for  boys     • No  signs  of  catch-­‐up  growth  in  previous  year     • Actual  height  deviates  >  1  SD  from  target  height  (TH)       • Children   were   excluded   if   other   reasons   than   those   related   to   GHD   or   SGA   for   growth  retardation  were  present   • SGA  children  with  GHD  are  excluded  in  this  study     Parents  and  children  were  informed  about  the  nature  of  the  study  and  written  con-­‐ sent   was   obtained.   The   study   was   approved   by   the   Medical   Ethical   Committee   of   the  Maastricht  University  Medical  Centre  (MUMC).   46    


Proefschrift binnenwerk Manon Ernst_DEF.indd
To see the actual publication please follow the link above